Fractyl's Revita Procedure Demonstrates Long-Term Weight Stability in REVEAL-1 Study

Fractyl Health reported six-month data from its REVEAL-1 study, showing that patients with obesity who stopped GLP-1 drugs maintained weight and glycemic control after a single Revita procedure. Participants who lost an average of 24% of body weight on GLP-1 medication showed only a 1.5% average weight change and nearly flat HbA1c levels six months after discontinuation. The findings support Revita's FDA Breakthrough Device designation and strengthen confidence ahead of clinical milestones in 2026.